264 related articles for article (PubMed ID: 14760423)
1. Genetic, cellular and immune approaches to disease therapy: past and future.
Nabel GJ
Nat Med; 2004 Feb; 10(2):135-41. PubMed ID: 14760423
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market.
Huang CJ; Lowe AJ; Batt CA
Appl Microbiol Biotechnol; 2010 Jun; 87(2):401-10. PubMed ID: 20422181
[TBL] [Abstract][Full Text] [Related]
3. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
Haurum JS
Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system.
Zlokovic BV; Apuzzo ML
Neurosurgery; 1997 Apr; 40(4):789-803; discussion 803-4. PubMed ID: 9092853
[TBL] [Abstract][Full Text] [Related]
5. Engineered antibody approaches for Alzheimer's disease immunotherapy.
Robert R; Wark KL
Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
[TBL] [Abstract][Full Text] [Related]
6. Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy.
Stryjewska A; Kiepura K; Librowski T; Lochyński S
Pharmacol Rep; 2013; 65(5):1086-101. PubMed ID: 24399705
[TBL] [Abstract][Full Text] [Related]
7. Engineering recombinant antibodies for immunotherapy.
Neri D; Petrul H; Roncucci G
Cell Biophys; 1995 Aug; 27(1):47-61. PubMed ID: 7493398
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing and human antibody repertoire analysis.
Boyd SD; Crowe JE
Curr Opin Immunol; 2016 Jun; 40():103-9. PubMed ID: 27065089
[TBL] [Abstract][Full Text] [Related]
9. Perspective on molecular immunology and modulation of immune responses.
Bloom BR
Cell Immunol; 1986 Apr; 99(1):61-72. PubMed ID: 3093103
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered antibodies in gene transfer and gene therapy.
Pelegrin M; Marin M; Noël D; Piechaczyk M
Hum Gene Ther; 1998 Oct; 9(15):2165-75. PubMed ID: 9794201
[TBL] [Abstract][Full Text] [Related]
11. The current state of cancer gene therapy and its application in esophageal carcinoma.
Buskens CJ; Marsman WA; Bosma PJ; van Lanschot JJ
Dig Surg; 2005; 22(4):222-33. PubMed ID: 16174979
[TBL] [Abstract][Full Text] [Related]
12. Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.
Stingl G; Brŏcker EB; Mertelsmann R; Wolff K; Schreiber S; Kămpgen E; Schneeberger A; Dummer W; Brennscheid U; Veelken H; Birnstiel ML; Zatloukal K; Schmidt W; Maass G; Wagner E; Baschle M; Giese M; Kempe ER; Weber HA; Voigt T
Hum Gene Ther; 1996 Mar; 7(4):551-63. PubMed ID: 8800750
[No Abstract] [Full Text] [Related]
13. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
14. Strategies for effective naked-DNA vaccination against infectious diseases.
Chiarella P; Massi E; De Robertis M; Fazio VM; Signori E
Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):93-101. PubMed ID: 18673122
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibody libraries and selection technologies.
Zhou H; Zhang YL; Lu G; Ji H; Rodi CP
N Biotechnol; 2011 Sep; 28(5):448-52. PubMed ID: 21477669
[TBL] [Abstract][Full Text] [Related]
16. Vaccine process technology.
Josefsberg JO; Buckland B
Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
[TBL] [Abstract][Full Text] [Related]
17. Recombinant antibodies and in vitro selection technologies.
Geyer CR; McCafferty J; Dübel S; Bradbury AR; Sidhu SS
Methods Mol Biol; 2012; 901():11-32. PubMed ID: 22723092
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells.
Noël D; Pelegrin M; Marin M; Biard-Piechaczyk M; Ourlin JC; Mani JC; Piechaczyk M
Hum Gene Ther; 1997 Jul; 8(10):1219-29. PubMed ID: 9215739
[TBL] [Abstract][Full Text] [Related]
19. T lymphocyte engineering ex vivo for cancer and infectious disease.
Levine BL
Expert Opin Biol Ther; 2008 Apr; 8(4):475-89. PubMed ID: 18352851
[TBL] [Abstract][Full Text] [Related]
20. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
Klener P; Etrych T; Klener P
Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
